Menu Close

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

– Intellia Will Receive a One-time $10 Million Payment Under the terms of the original agreement, Novartis received exclusive rights to develop all collaboration programs focused on engineered … (본문 전체 12/6/2018 9:30 PM)